Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE6671) than lymphokine activated killer cells from peripheral blood

Child's Nervous System

Volumn 20, Issue 3, 2004, Pages 154-162

  Kang, Seok Gu ^a   Ryu, Chung Hun ^b   Jeun, Sin Soo ^b   Park, Chun Kun ^b   Shin, Hyung Jin ^a   Kim, Jong Hyun ^a   Kim, Moon Chan ^b   Kang, Joon Ki ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Anaplastic astrocytoma; Interleukin 2; Lymphokine activated killer cells; Medulloblastoma; Umbilical cord blood

Indexed keywords

DNA FRAGMENT; FAS LIGAND; INTERLEUKIN 2; PERFORIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL ASSAY; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; EFFECTOR CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOKINE ACTIVATED KILLER CELL; MEDULLOBLASTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; UMBILICAL CORD BLOOD;

ADULT; APOPTOSIS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CEREBELLAR NEOPLASMS; CHILD; CYTOTOXICITY TESTS, IMMUNOLOGIC; FAS LIGAND PROTEIN; FETAL BLOOD; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFANT, NEWBORN; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTES, TUMOR-INFILTRATING; MEDULLOBLASTOMA; MEMBRANE GLYCOPROTEINS; PORE FORMING CYTOTOXIC PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 1842477504     PISSN: 02567040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00381-003-0898-7     Document Type: Article

References (56)

1. Ballas ZK, Rasmussen W (1993) Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1+CD8 alpha+beta-TCR-alpha beta B220+ lymphokine-activated killer subset. J Immunol 150:17-30
2. Bhagwati SN (1989) Treatment of glioma with intratumoral instillation of autologous lymphocytes. Childs Nerv Syst 5:38-40
3. Boiardi A, Silvani A, Ruffini PA, Rivoltini L, Parmiani G, Broggi G, Salmaggi A (1994) Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 39:193-197
4. Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97:77-89
5. Chang L, Gusewitch GA, Chritton DB, Folz JC, Lebeck LK, Nehlsen-Cannarella SL (1993) Rapid flow cytometric assay for the assessment of natural killer cell activity. J Immunol Methods 166:45-54
6. Condiotti R, Nagler A (1998) Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells. Exp Hematol 26:571-579
7. Devine SM, Lazarus HM, Emerson SG (2003) Clinical application of hematopoietic progenitor cell expansion: Current status and future prospects. Bone Marrow Transplant 31:241-252
8. Dominguez E, Madrigal JA, Layrisse Z, Cohen SB (1998) Fetal natural killer cell function is suppressed. Immunology 94:109-114
9. Fagioli F, Biasin E, Berger M, Nesi F, Saroglia EH, Miniero R, Martino S, Tovo PA (2003) Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency syndrome. Bone Marrow Transplant 31:133-136
10. Frenkel L, Bryson YJ (1987) Ontogeny of phytohemagglutinin-induced gamma interferon by leukocytes of healthy infants and children: Evidence for decreased production in infants younger than 2 months of age. J Pediatr 111:97-100
11. Fujimiya Y, Suzuki Y, Katakura R, Ohno T (1999) Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients. J Hematother 8:29-37
12. Gaddy J, Broxmeyer HE (1997) Cord blood CD16+56-cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol 180:132-142
13. George RE, Loudon WG, Moser RP, Bruner JM, Steck PA, Grimm EA (1988) In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. J Neurosurg 69:403-409
14. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P et al (1989) Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321:1174-1178
15. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, Ortega J, Souillet G, Ferreira E, Laporte JP, Fernandez M, Chastang C (1997) Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 337:373-381
16. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823-1841
17. Harris DT (1995) In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transplant 15:17-23
18. Harris DT, Schumacher MJ, Locascio J, Besencon FJ, Olson GB, DeLuca D, Shenker L, Bard J, Boyse EA (1992) Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proc Natl Acad Sci USA 89:10006-10040
19. Harris DT, LoCascio J, Besencon FJ (1994) Analysis of the alloreactive capacity of human umbilical cord blood: Implications for graft-versus-host disease. Bone Marrow Transplant 14:545-553
20. Hassall O, Bedu-Addo G, Adarkwa M, Danso K, Bates I (2003) Umbilical-cord blood for transfusion in children with severe anaemia in under-resourced countries. Lancet 361:678-679
21. Hayes RL (1992) The cellular immunotherapy of primary brain tumors. Rev Neurol (Paris) 148:454-466
22. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76:840-852
23. Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, Zaroulis C (2001) Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol 39:31-42
24. Huang Y, Hayes RL, Wertheim S, Arbit E, Scheff R (2001) Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: A case report. Crit Rev Oncol Hematol 39:17-23
25. Itoh K, Sawamura Y, Hosokawa M, Kobayashi H (1988) Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor. Radiat Med 6:276-281
26. Itoh N, Yonehara S, Ishii A, Yonehara. M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243
27. Jacobs SK, Melin G, Holcomb B, Parham CW, Kornblith PL, Grimm EA (1986) Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: Trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells. Brain Res 372:386-389
28. Jacobs SK, Wilson DJ, Melin G, Parham CW, Holcomb B, Kornblith PL, Grimm EA (1986) Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: Clinical and experimental studies. Neurol Res 8:81-87
29. Jacobs SK, Parham CW, Holcomb B, Ikejiri B, Kornblith PL, Grimm EA (1987) Lymphokine activated killer (LAK) cell mediated killing of human glioma: Effect of pretreating glioma with various membrane modifying agents. J Neurooncol 5:5-10
30. Joshi SS, Babushkina-Patz NN, Verbik DJ, Gross TG, Tarantolo SR, Kuszynski CA, Pirruccello SJ, Bishop MR, Kessinger A (1998) Antitumor activity of human umbilical cord blood cells: A comparative analysis with peripheral blood and bone marrow cells. Int J Oncol 13:791-799
31. Joshi SS, Tarantolo SR, Kuszynski CA, Kessinger A (2000) Antitumor therapeutic potential of activated human umbilical cord blood cells against leukemia and breast cancer. Clin Cancer Res 6:4351-4358
32. Kikuchi T, Joki T, Abe T, Ohno T (1999) Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells. J Immunother 22:245-250
33. Kim H, Lee H, Yun Y (1998) X-gene product of hepatitis B virus induces apoptosis in liver cells. J Biol Chem 273:381-385
34. Kruse CA, Mitchell DH, Lillehei KO, Johnson SD, McCleary EL, Moore GE, Waldrop S, Mierau GW (1989) Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro. Cancer 64:1629-1637
35. Lovgren TR, Tarantolo SR, Evans C, Kuszynski CA, Joshi SS (2002) Enhanced in vitro and in vivo cytotoxicity of umbilical cord blood cells against human breast cancer following activation with IL-15 and colony stimulating factors. In Vivo 16:541-550
36. Merchant RE, Ellison MD, Young HF (1990) Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations. J Neurooncol 8:173-188
37. Montagna D, Maccario R, Ugazio AG, Mingrat G, Burgio GR (1988) Natural cytotoxicity in the neonate: High levels of lymphokine activated killer (LAK) activity. Clin Exp Immunol 71:177-181
38. Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007-1008
39. Morse MA, Clay TM, Lyerly HK (2002) Current status of adoptive immunotherapy of malignancies. Expert Opin Biol Ther 2:237-247
40. Naganuma H, Sasaki A, Satoh E, Nagasaka M, Isoe S, Nakano S, Nukui H (1997) Long-term survival in a young patient with anaplastic glioma. Brain Tumor Pathol 14:71-74
41. Nomura A, Takada H, Jin CH, Tanaka T, Ohga S, Hara T (2001) Functional analyses of cord blood natural killer cells and T cells: A distinctive interleukin-18 response. Exp Hematol 29:1169-1176
42. Okamoto Y, Shimizu K, Tamura K, Miyao Y, Yamada M, Matsui Y, Tsuda N, Takimoto H, Hayakawa T, Mogami H (1988) An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien) 94:47-52
43. Radosevic K, Garritsen HS, Van Graft M, De Grooth BG, Greve J (1990) A simple and sensitive flow cytometric assay for the determination of the cytotoxic activity of human natural killer cells. J Immunol Methods 135:81-89
44. Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E (2000) Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 342:1846-1854
45. Sankhla SK, Nadkarni JS, Bhagwati SN (1996) Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol 27:133-140
46. Smyth MJ, McGuire MJ, Thia KY (1995) Expression of recombinant human granzyme B. A processing and activation role for dipeptidyl peptidase I. J Immunol 154:6299-6305
47. Smyth MJ, Trapani JA (1995) Granzymes: Exogenous proteinases that induce target cell apoptosis. Immunol Today 16:202-206
48. Suen Y, Lee SM, Qian J, van de Ven C, Cairo MS (1998) Dysregulation of lymphokine production in the neonate and its impact on neonatal cell mediated immunity. Vaccine 16:1369-1377
49. Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 21:1581-1591
50. Ting CC, Hargrove ME (1992) IL-4 regulation of a protein kinase C independent pathway for the generation of alpha CD3-induced activated killer cells. Cell Immunol 140:130-144
51. Tzeng JJ, Barth RF, Clendenon NR, Gordon WA (1990) Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res 50:4338-4343
52. Vu UE, Pavletic ZS, Wang X, Joshi SS (2000) Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: Potentials for therapeutic use. Leuk Lymphoma 39:573-582
53. Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies SM, Ramsay NK, McGlave PB, Sender L, Cairo MS (1996) Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: Analysis of engraftment and acute graft-versus-host disease. Blood 88:795-802
54. Wilson CB, Westall J, Johnston L, Lewis DB, Dower SK, Alpert AR (1986) Decreased production of interferon-gamma by human neonatal cells. Intrinsic and regulatory deficiencies. J Clin Invest 77:860-867
55. Yoshida J, Takaoka T, Mizuno M, Momota H, Okada H (1996) Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha. J Surg Oncol 62:177-182
56. Zychlinsky A, Zheng LM, Liu CC, Young JD (1991) Cytolytic lymphocytes induce both apoptosis and necrosis in target cells. J Immunol 146:393-400